---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-105657"
form_type: "8-K"
ticker: null
cik: "0001178879"
company_name: "AMICUS THERAPEUTICS, INC."
filed_at: "2023-10-02T23:59:59+00:00"
generated_at: "2026-06-10T06:16:25.143064+00:00"
event_type: "debt"
sentiment: "positive"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Amicus Therapeutics secures $430M financing from Blackstone: $400M term loan + $30M equity

## Summary
- $400M senior secured term loan at adjusted Term SOFR +6.25% (2.50% floor on SOFR), interest-only until late 2026, matures Oct 2029.
- Proceeds used to refinance existing debt and fund operations; $30M private placement of 2.47M shares at $12.16/share.
- Loan amortization begins Q4 2026 with 12 quarterly payments of $33.33M; prepayment penalties decline over 5 years.
- Equity investors (Blackstone funds) subject to 60-day lock-up; registration statement to be filed by Nov 9, 2023.
- Minimum liquidity covenant of $100M and minimum revenue covenant of $225M (trailing 4 quarters) included.

## SEC filing metadata
- accession: 0001104659-23-105657
- form_type: 8-K
- cik: 0001178879
- company_name: AMICUS THERAPEUTICS, INC.
- filed_at: 2023-10-02T23:59:59+00:00
- event_type: debt
- sentiment: positive
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 1.01, 2.03, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1178879/000110465923105657/0001104659-23-105657-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1178879/000110465923105657/tm2327120d2_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-105657
- JSON: https://secwatch.observer/filing/0001104659-23-105657.json
- Plain text: https://secwatch.observer/filing/0001104659-23-105657.txt

## Key facts
- Debt Financings
  AMICUS THERAPEUTICS, INC. incurred term loan of $400 million with Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C. at 3-month Term SOFR, subject to a 2.5% floor, plus a Term SOFR adjustment of 0.261 maturing six years from the date of the funding of the Term Loan.
  - Instrument: term loan
  - Principal: $400 million
  - Counterparty: Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C.
  - Rate: 3-month Term SOFR, subject to a 2.5% floor, plus a Term SOFR adjustment of 0.261
  - Maturity: six years from the date of the funding of the Term Loan
  - Event: incurrence
  source text: respective meanings ascribed to such terms in the Loan Agreement, a copy of which is filed as Exhibit 10.1 to this Current Report on Form 8-K. The Loan Agreement provides for a $400 million senior secured Term Loan to be extended to Amicus, on or about October 5, 2023, subject to entry into a security agreement and delivery of other customary deliverables. The
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178879/000110465923105657/0001104659-23-105657-index.htm
- Material Agreements
  AMICUS THERAPEUTICS, INC. entered into Purchase Agreement with purchasers set forth on Schedule A attached thereto (the “Purchasers”), which are all funds managed by Blackstone valued at aggregate of 2,467,104 shares of the Company’s common stock, at a purchase price of $12.16 per share (effective 2023-10-02).
  - Action: entry
  - Agreement: equity purchase
  - Counterparty: purchasers set forth on Schedule A attached thereto (the “Purchasers”), which are all funds managed by Blackstone
  - Value: aggregate of 2,467,104 shares of the Company’s common stock, at a purchase price of $12.16 per share
  - Effective: 2023-10-02
  source text: On October 2, 2023, Amicus entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers set forth on Schedule A attached thereto (the “Purchasers”), which are all funds managed by Blackstone, for the private placement (the “Private Placement”) of an aggregate of 2,467,104 shares of the Company’s common stock, at a purchase price of $12.16 per share (the “Common Stock”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178879/000110465923105657/0001104659-23-105657-index.htm
- Material Agreements
  AMICUS THERAPEUTICS, INC. entered into Loan Agreement with Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C. valued at $400 million senior secured Term Loan (effective 2023-10-02).
  - Action: entry
  - Agreement: credit facility
  - Counterparty: Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C.
  - Value: $400 million senior secured Term Loan
  - Effective: 2023-10-02
  source text: On October 2, 2023, Amicus Therapeutics, Inc., a Delaware corporation (“Amicus” or the “Company”) entered into a Loan Agreement (the “Loan Agreement”), by and among Amicus, as the borrower (the “Borrower”), certain subsidiaries of Amicus from time to time party thereto as guarantors (the “Guarantors”), Blackstone Alternative Credit Advisors LP and Blackstone Life Sciences Advisors L.L.C. (collectively, the “Blackstone Representative” and referred to herein as “Blackstone”) and Wilmington Trust, National Association, as Agent (the “Agent”) for certain lenders from time to time party thereto (collectively, the “Lenders”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1178879/000110465923105657/0001104659-23-105657-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.